New eye drug aims to stop diabetic vision loss

NCT ID NCT07588100

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental drug called RO7663498, given as an injection into the eye, for people with diabetic retinopathy. The main goal is to check safety and how the drug moves through the body. About 30 participants will receive multiple doses to see if it is well-tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

RO7663498 (injected into the eye)

What this could lead to

If it works, this could point toward a new treatment to control diabetic retinopathy and prevent vision loss.

What could go wrong

This is a very early Phase 1 trial with only 30 people, focused on safety. It may not show any benefit, and eye injections carry risks like infection or inflammation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

background diabetic retinopathy diabetic retinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Global Research Management

    RECRUITING

    Glendale, California, 91204, United States